SEC Comment Letter 0000000000-24-011665 to Zentalis Pharmaceuticals, Inc. (ZNTL)

Zentalis Pharmaceuticals, Inc.
Date: Oct. 17, 2024 · CIK: 0001725160 · Accession: 0000000000-24-011665

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-39263

Date

October 17, 2024

Author

Cam Gallagher

Form

UPLOAD

Company

Zentalis Pharmaceuticals, Inc.

Letter

October 17, 2024 Cam Gallagher Interim Chief Financial Officer Zentalis Pharmaceuticals, Inc. 1359 Broadway Suite 801 New York, New York 10018 Re:Zentalis Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 Filed February 27, 2024 File No. 001-39263 Dear Cam Gallagher: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

October 17, 2024
Cam Gallagher
Interim Chief Financial Officer
Zentalis Pharmaceuticals, Inc.
1359 Broadway
Suite 801
New York, New York 10018
Re:Zentalis Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2023
Filed February 27, 2024
File No. 001-39263
Dear Cam Gallagher:
            We have completed our review of your filings. We remind you that the company and
its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io